Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.

Valerie ReliasAli McBrideMatthew J NewmanShilpa PaulSeyyedeh SaneeymehriGenique StanislausJennifer TobinCaroline J HoangJoanne C RyanIlene Galinsky

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Pharmacists and advanced practitioners play important roles in treatment with glasdegib plus LDAC. Ultimately, framing plans for treatment delivery within the individual circumstances of each patient may enable them to stay on therapy longer, giving them the greatest potential to achieve benefit.

Keyphrases

acute myeloid leukemia
low dose
primary care
general practice
high dose
stem cells
acute lymphoblastic leukemia
bone marrow
allogeneic hematopoietic stem cell transplantation
climate change
cell therapy
smoking cessation